Go to:
Logótipo
Comuta visibilidade da coluna esquerda
Você está em: Start > Publications > View > The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells
Publication

The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells

Title
The Main Metabolites of Fluorouracil + Adriamycin + Cyclophosphamide (FAC) Are Not Major Contributors to FAC Toxicity in H9c2 Cardiac Differentiated Cells
Type
Article in International Scientific Journal
Year
2019
Authors
Reis Mendes, A
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Felix Carvalho
(Author)
FFUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Fernando Remiao
(Author)
FFUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Emilia Sousa
(Author)
FFUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page Without ORCID
Maria de Lourdes Bastos
(Author)
FFUP
View Personal Page You do not have permissions to view the institutional email. Search for Participant Publications View Authenticus page View ORCID page
Costa, VM
(Author)
Other
The person does not belong to the institution. The person does not belong to the institution. The person does not belong to the institution. Without AUTHENTICUS Without ORCID
Journal
Title: BiomoleculesImported from Authenticus Search for Journal Publications
Vol. 9 No. 9
Final page: 98
ISSN: 2218-273X
Publisher: MDPI
Other information
Authenticus ID: P-00Q-AXH
Abstract (EN): In the clinical practice, the combination of 5-fluorouracil (5-FU) + Adriamycin (also known as doxorubicin, DOX) + cyclophosphamide (CYA) (known as FAC) is used to treat breast cancer. The FAC therapy, however, carries some serious risks, namely potential cardiotoxic effects, although the mechanisms are still unclear. In the present study, the role of the main metabolites regarding FAC-induced cardiotoxicity was assessed at clinical relevant concentrations. Seven-day differentiated H9c2 cells were exposed for 48 h to the main metabolites of FAC, namely the metabolite of 5-FU, ¿-fluoro-ß-alanine (FBAL, 50 or 100 ¿M), of DOX, doxorubicinol (DOXOL, 0.2 or 1 ¿M), and of CYA, acrolein (ACRO, 1 or 10 ¿M), as well as to their combination. The parent drugs (5-FU 50 ¿M, DOX 1 ¿M, and CYA 50 ¿M) were also tested isolated or in combination with the metabolites. Putative cytotoxicity was evaluated through phase contrast microscopy, Hoechst staining, membrane mitochondrial potential, and by two cytotoxicity assays: the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) and the neutral red (NR) lysosomal incorporation. The metabolite DOXOL was more toxic than FBAL and ACRO in the MTT and NR assays. When in combination, neither FBAL nor ACRO increased DOXOL-induced cytotoxicity. No nuclear condensation was observed for any of the tested combinations; however, a significant mitochondrial potential depolarization after FBAL 100 ¿M + DOXOL 1 ¿M + ACRO 10 ¿M or FBAL 100 ¿M + DOXOL 1 ¿M exposure was seen at 48 h. When tested alone DOX 1 ¿M was more cytotoxic than all the parent drugs and metabolites in both the cytotoxicity assays performed. These results demonstrated that DOXOL was the most toxic of all the metabolites tested; nonetheless, the metabolites do not seem to be the major contributors to FAC-induced cardiotoxicity in this cardiac model.
Language: English
Type (Professor's evaluation): Scientific
No. of pages: 20
Documents
We could not find any documents associated to the publication.
Related Publications

Of the same authors

Unveiling the cardiotoxicity of anticancer drugs: A comparative in vitro study between mitoxantrone and its naphthoquinoxaline metabolite (2015)
Other Publications
Reis Mendes, A; Gomes, AS; Carvalho, RA; Fernando Remiao; Felix Carvalho; Pinto, M; Maria de Lourdes Bastos; Emilia Sousa; Costa, VM
Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy (2017)
Article in International Scientific Journal
Reis Mendes, A; Gomes, AS; Carvalho, RA; Felix Carvalho; Fernando Remiao; Pinto, M; Maria de Lourdes Bastos; Emilia Sousa; Costa, VM
Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells (2022)
Article in International Scientific Journal
Reis Mendes, A; Felix Carvalho; Fernando Remiao; Emilia Sousa; Maria de Lourdes Bastos; Costa, VM

Of the same journal

The Impact of Flavonoid-Loaded Nanoparticles in the UV Protection and Safety Profile of Topical Sunscreens (2023)
Another Publication in an International Scientific Journal
Fonseca, M; Rehman, M; soares, r; Fonte, P
Stalling the Course of Neurodegenerative Diseases: Could Cyanobacteria Constitute a New Approach toward Therapy? (2023)
Another Publication in an International Scientific Journal
Ramos, V; Reis, M; Ferreira, L; Silva, AM; Ferraz, R; Vieira, M; Vitor Vasconcelos; Martins, R
Saquinavir: From HIV to COVID-19 and Cancer Treatment (2022)
Another Publication in an International Scientific Journal
Pereira, M; Nuno Vale
Natural Sympathomimetic Drugs: From Pharmacology to Toxicology (2022)
Another Publication in an International Scientific Journal
Costa, VM; Grando, LGR; Milandri, E; Nardi, J; Teixeira, P; Mladenka, P; Fernando Remiao
Natural Ergot Alkaloids in Ocular Pharmacotherapy: Known Molecules for Novel Nanoparticle-Based Delivery Systems (2020)
Another Publication in an International Scientific Journal
Baldim, I; Oliveira, WP; Kadian, V; Rao, R; Yadav, N; Mahant, S; Lucarini, M; Durazzo, A; Da Ana, R; Capasso, R; Souto, SB; Santini, A; Souto, EB

See all (51)

Recommend this page Top